Klotho and the Treatment of Human Malignancies.
Loading...
Embargo End Date
ICR Authors
Authors
Sachdeva, A
Gouge, J
Kontovounisios, C
Nikolaou, S
Ashworth, A
Lim, K
Chong, I
Gouge, J
Kontovounisios, C
Nikolaou, S
Ashworth, A
Lim, K
Chong, I
Document Type
Journal Article
Date
2020-06-23
Date Accepted
2020-06-16
Abstract
Klotho was first discovered as an anti-ageing protein linked to a number of age-related disease processes, including cardiovascular, renal, musculoskeletal, and neurodegenerative conditions. Emerging research has also demonstrated a potential therapeutic role for Klotho in cancer biology, which is perhaps unsurprising given that cancer and ageing share similar molecular hallmarks. In addition to functioning as a tumour suppressor in numerous solid tumours and haematological malignancies, Klotho represents a candidate therapeutic target for patients with these diseases, the majority of whom have limited treatment options. Here, we examine contemporary evidence evaluating the anti-neoplastic effects of Klotho and describe the modulation of downstream oncogenic signalling pathways, including Wnt/β-catenin, FGF, IGF1, PIK3K/AKT, TGFβ, and the Unfolded Protein Response. We also discuss possible approaches to developing therapeutic Klotho and consider technological advances that may facilitate the delivery of Klotho through gene therapy.
Citation
Cancers, 2020, 12 (6)
Source Title
Publisher
MDPI
ISSN
2072-6694
eISSN
2072-6694
Collections
Research Team
Ashworth Collaborators